All In MedTech

FDA Clearance Tracker · P230035

AGENT Paclitaxel-Coated Balloon Catheter

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Feb 29, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Feb 29, 2024

Approved

Time to decision

147 days

Received Oct 5, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230035
Device name
AGENT Paclitaxel-Coated Balloon Catheter
Applicant location
Maple Grove, MN
Received
Oct 5, 2023
Decided
Feb 29, 2024
Decision
Approved
Supplements
8 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OOB

FDA's approval statement

As written in FDA's record.

The AGENT Paclitaxel-Coated Balloon Catheter is intended to be used after appropriate vessel preperation in adult patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OOB (Drug-eluting percutaneous transluminal coronary angioplasty catheter).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.